Agreement for 3DP, J&J
research term under its thrombin collaboration with two of the
Johnson & Johnson family of companies, Centocor and Johnson
& Johnson Pharmaceutical Research and Development, L.L.C., has
been extended up until December 2003.
3-Dimensional Pharmaceuticals (3DP) said this week that the research term under its thrombin collaboration with two of the Johnson & Johnson family of companies, Centocor and Johnson & Johnson Pharmaceutical Research and Development, L.L.C., has been extended up until December 2003.
Under the extension, 3DP will receive approximately $1.4 million (€1.3m) in additional research funding and will continue to be eligible for milestone payments and royalties on sales of any products marketed under the agreement.
The original agreement granted worldwide rights to 3DP's orally active direct thrombin inhibitor program to Centocor in December 2000. Since entering into the collaboration, the companies have expanded it to include inhibitors of other targets. In October 2001, 3DP received a $4 million development milestone payment under the agreement.
3DP is an integrated bio-pharmaceuticals company currently investigating small molecule drug discovery and development.
